Teladoc Health Narrows FY2025 GAAP EPS Guidance from $(1.40)-$(0.90) to $(1.35)-$(1.00) vs $(1.08) Est; Narrows FY2025 Sales Guidance from $2.468B-$2.576B to $2.501B-$2.548B vs $2.517B Est
Author: Benzinga Newsdesk | July 29, 2025 04:12pm
Teladoc Health (NYSE:
TDOC) narrows FY2025 GAAP EPS guidance from $(1.40)-$(0.90) to $(1.35)-$(1.00) vs $(1.08) analyst estimate. Narrows FY2025 sales outlook from $2.468 billion-$2.576 billion to $2.501 billion-$2.548 billion vs $2.517 billion estimate.
Posted In: TDOC